Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies

Reuters09-04

Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies

Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. $(ELAB)$, has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova™ AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523447-en) on September 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2564370270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564370270","market":"us","top_or_hot":-1,"title":"Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. <a href=\"https://laohu8.com/S/ELAB\">$(ELAB)$</a>, has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova™ AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523447-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNorthstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. <a href=\"https://laohu8.com/S/ELAB\">$(ELAB)$</a>, has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova™ AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523447-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDLbQm3y6:1","article_id":"2564370270","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564370270","pubTimestamp":1756994064,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. , has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4183":"个人用品","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","ELAB":"PMGC Holdings","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"PMGC Holdings子公司Northstrive Biosciences完成肥胖治疗人工智能项目的第二阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ELAB":0.9},"content_text":"Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies\n    \n\n        Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. $(ELAB)$, has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova™ AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523447-en) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564370270","isCrawlerRequest":true}